Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Kosan Biosciences Incorporated - KOSN - Annual Report' returned 29 results - Page 1 of 2   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Multiple Myeloma Therapeutics - US Market Trends & Analysis   Bizacumen Inc., Nov 2009, Pages: 347 Bristol-Myers to Take Over Kosan Biosciences 35 Bristol and PDL BioPharma Enter into Agreement 35 Gamida Cell Enters Into a Agreement with Amgen Digestive System Gastroesophageal Reflux Disease   Life Science Analytics, March 2008, Pages: 123 Disease Projects --Addex Pharmaceuticals SA --AstraZeneca Plc --Dynogen Pharmaceuticals, Inc. --Kosan Biosciences Incorporated --MOVETIS NV --Pfizer Inc --Takeda Pharmaceutical Company Limited Pipeline Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances   Decision Resources, Inc., Aug 2008, Pages: 33 Pharmaceutica - Johnson & Johnson - Kosan Biosciences - Kyowa Hakko - Massachusetts Institute of Technology - MedImmune - Merck - Merck Serono - Mirabila - MorphoSys - Morphotek - Neurimmune Therapeutics Digestive System - Gastroesophageal Reflux Disease Drug Pipeline Report   Life Science Analytics, June 2007, Pages: 13 in early stage Gastroesophageal Reflux Disease Projects --Addex Pharmaceuticals SA --AstraZeneca Plc --Dynogen Pharmaceuticals, Inc. --Kosan Biosciences Incorporated --MOVETIS NV --NPS Pharmaceuticals Inc Who's Developing What in New Cancer Drugs?   Espicom Business Intelligence Ltd, Nov 2007, Pages: 1500 Pharmaceuticals Keryx Biopharmaceuticals Kirin Holdings Company Kosan Biosciences Kyowa Hakko Kogyo Ligand Pharmaceuticals Lorus Therapeutics Marshall Edwards Medarex MediGene Merck KGaA Methyl The 2011 Report on Multiple Myeloma Therapeutics: World Market Segmentation by City   ICON Group International, Jan 2011, Pages: 329 . In the case of this report, the data were reported at the aggregate level, with no further breakdown or definition. In other words, any potential product or service that might be incorporated within multiple The 2011-2016 Outlook for Multiple Myeloma Therapeutics in Africa   ICON Group International, Jan 2011, Pages: 56 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2011-2016 Outlook for Multiple Myeloma Therapeutics in Asia & the Middle East   ICON Group International, Jan 2011, Pages: 56 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2011-2016 Outlook for Multiple Myeloma Therapeutics in Europe   ICON Group International, Jan 2011, Pages: 54 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2011-2016 Outlook for Multiple Myeloma Therapeutics in Latin America   ICON Group International, Jan 2011, Pages: 35 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2011-2016 Outlook for Multiple Myeloma Therapeutics in North America & the Caribbean   ICON Group International, Jan 2011, Pages: 37 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2011-2016 Outlook for Multiple Myeloma Therapeutics in Oceana   ICON Group International, Jan 2011, Pages: 34 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2011-2016 World Outlook for Multiple Myeloma Therapeutics   ICON Group International, Jan 2011, Pages: 195 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2011-2016 Outlook for Multiple Myeloma Therapeutics in Greater China   ICON Group International, Jan 2011, Pages: 142 .e., a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e., the figures incorporate inflationary trends The 2011-2016 Outlook for Multiple Myeloma Therapeutics in India   ICON Group International, Jan 2011, Pages: 319 of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e., the figures incorporate inflationary trends). If inflation The 2011-2016 Outlook for Multiple Myeloma Therapeutics in Japan   ICON Group International, Jan 2011, Pages: 141 of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e., the figures incorporate inflationary trends). If inflation The 2011-2016 Outlook for Multiple Myeloma Therapeutics in the United States   ICON Group International, Jan 2011, Pages: 731 .e., a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e., the figures incorporate inflationary trends The 2010 Report on Multiple Myeloma Therapeutics: World Market Segmentation by City   ICON Group International, July 2009, Pages: 329 . In the case of this report, the data were reported at the aggregate level, with no further breakdown or definition. In other words, any potential product or service that might be incorporated within multiple The 2010-2015 Outlook for Multiple Myeloma Therapeutics in Asia   ICON Group International, May 2009, Pages: 38 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends The 2010-2015 Outlook for Multiple Myeloma Therapeutics in The Americas & the Caribbean   ICON Group International, May 2009, Pages: 54 .e. a calculation of price times quantity is never made, though one is implied). The units used in this report are U.S. dollars not adjusted for inflation (i.e. the figures incorporate inflationary trends Results:  First -   Prev -   1 -   2 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network